Actively Recruiting
Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa
Led by University of Minnesota · Updated on 2026-02-17
16
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
HS is relatively common in the United States with a prevalence of 0.1-1.0%. 1 HS has a dramatic impact on quality of life, significantly more so than other chronic skin diseases, such as psoriasis or atopic dermatitis (AD). HS also has a large economic impact, due to frequent emergency department and inpatient care utilization, and re-hospitalization rates similar to congestive heart failure. Unfortunately, few treatment options are effective. There are currently three FDA-approved treatments for HS, including adalimumab, secukinumab, and bimekizumab, each with only 40- 60% respond to treatment and over 50% lose response within one year . The overarching goal of this pilot study is to investigate the central hypothesis that oral microbiota transplant therapy(MTT) alters the gut microbiome in patients with Hidradenitis Suppurativa (HS), influencing cutaneous microbiota via systemically absorbed gut-derived metabolites.
CONDITIONS
Official Title
Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able and willing to provide informed consent
- English speaking
- Age 18 years or older
- Diagnosis of hidradenitis suppurativa by a dermatologist
- Women who are not post-menopausal or surgically sterile must use highly effective birth control or remain abstinent
- Able to comply with study measures as determined by the investigator
- Stable doses of all medications for 30 days prior to baseline
You will not qualify if you...
- Non-English speaking
- Refusal or inability to provide informed consent
- Planning to move within 6 months from start of study
- Allergy to neomycin or vancomycin
- Anaphylactic food allergies
- Pregnancy, breastfeeding, or planning pregnancy during study (negative pregnancy test required for persons of childbearing potential)
- Use of any topical or oral antibiotics within 30 days of randomization
- Use of any oral antibiotics within 90 days of randomization
- History of inflammatory bowel disease
- Extensive bowel resection
- Major bowel surgery within 4 weeks prior to baseline or planned during study
- Active skin disease other than HS that could interfere with assessments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Minnesota
Minneapolis, Minnesota, United States, 55414
Actively Recruiting
Research Team
T
Thomas Pritchard
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here